The follistatin/activin/myostatin axis represents an emerging therapeutic target for neurodegenerative diseases. This growth factor pathway regulates muscle mass, modulates neuroinflammation, and influences synaptic plasticity. Myostatin (MSTN), a member of the TGF-β superfamily, is a potent negative regulator of muscle growth. Follistatin (FST) binds and neutralizes myostatin and activins, promoting muscle hypertrophy. Growing evidence suggests that manipulating this axis may have beneficial effects on brain function in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
flowchart TD
A["Follistatin/Activin/Myostatin Axis"] --> B["Myostatin MSTN"]
A --> C["Activin A INHBA"]
A --> D["Activin B INHBB"]
B --> E["ActRIIB Receptor"]
C --> E
D --> E
E --> F["Smad2/3 Signaling"]
F --> G["Inhibits Muscle Growth"]
F --> H["Modulates Neuroinflammation"]
F --> I["Alters Synaptic Plasticity"]
J["Follistatin FST"] --> K["Neutralizes Myostatin"]
J --> L["Neutralizes Activins"]
K --> M["Promotes Muscle Growth"]
L --> M
M --> N["Increases Myokine Release"]
N --> O["Brain: Cognitive Benefits"]
style A fill:#e3f2fd
style J fill:#c8e6c9
style O fill:#fff9c4
Myostatin (MSTN) is a secreted growth differentiation factor (GDF-8) that acts as a master regulator of skeletal muscle mass. It signals through the activin type IIB receptor (ActRIIB/ACVR2B), activating Smad2/3 signaling to inhibit muscle protein synthesis and promote muscle atrophy.
Key characteristics:
- Expressed primarily in skeletal muscle
- Negatively regulates muscle fiber size and number
- Elevated levels associated with sarcopenia in aging and neurodegenerative diseases
- Genetic deficiency leads to muscle hypertrophy (documented in humans and animals)
Activin A (INHBA subunit) is a TGF-β superfamily member with important functions in the central nervous system:
- Modulates dendritic spine morphology and synaptic plasticity
- Elevated in AD and PD post-mortem brain tissue
- Involved in neuroinflammation regulation
- May contribute to excitotoxicity in ALS
Follistatin is a secreted glycoprotein that binds with high affinity to myostatin and activins, neutralizing their activity. By blocking this axis, follistatin promotes muscle growth and may have neuroprotective effects.
In AD, the follistatin/activin/myostatin axis offers multiple therapeutic opportunities:
- Cognitive Improvement: Myostatin inhibition improves learning and memory in AD mouse models
- Muscle-Brain Axis: Enhanced muscle activity increases release of myokines (irisin, BDNF) that benefit brain function
- Neuroinflammation: Activin A modulation reduces microglial activation and pro-inflammatory cytokine release
- Sarcopenia Management: Counteracts age-related muscle loss that correlates with cognitive decline
In PD, therapeutic targeting addresses:
- Motor Function: Myostatin inhibition improves motor performance in PD models
- Dopaminergic Protection: Follistatin may protect substantia nigra neurons from degeneration
- Muscle Strength: Counteracts PD-associated sarcopenia and improves mobility
- Quality of Life: Maintaining muscle function extends independent living
In ALS, the axis targets:
- Muscle Wasting: Myostatin inhibition may slow progressive muscle atrophy
- Motor Neuron Support: Activin A modulation may reduce excitotoxicity
- Respiratory Function: Preserving diaphragm muscle function prolongs respiratory capacity
¶ Therapeutic Candidates
| Drug |
Company |
Mechanism |
Status |
Indication |
| MYO-029 |
Wyeth/Pfizer |
Myostatin antibody |
Phase 2 (completed) |
Muscular dystrophy |
| Stamulumab |
Wyeth |
Myostatin antibody |
Phase 2 |
Muscular dystrophy |
| RK-35 |
Regeneron |
Myostatin antibody |
Preclinical |
Various |
| YRS-003 |
Y's Therapeutics |
Myostatin antibody |
Phase 1 |
Sarcopenia |
| Drug |
Mechanism |
Status |
Notes |
| ACE-031 |
ActRIIB receptor decoy |
Phase 2 |
Accelerated muscle growth |
| Bimagrumab |
ActRIIB antibody |
Phase 2/3 |
Blocks myostatin binding |
- AAV-Follistatin: Gene therapy delivering follistatin to muscle
- Promotes sustained myostatin/activin blockade
- Phase 1 trials for muscular dystrophy showed safety and muscle growth
- Potential for neurodegenerative disease applications
| Compound |
Mechanism |
Development Stage |
| MYO-029 |
Antibody |
Phase 2 completed |
| Various |
ActRIIB antagonists |
Preclinical |
| NCT ID |
Intervention |
Phase |
Disease |
Key Findings |
| NCT00104078 |
MYO-029 |
Phase 2 |
Muscular dystrophy |
Safe, increased muscle mass |
| NCT00773240 |
Stamulumab |
Phase 2 |
Muscular dystrophy |
Dose-dependent strength increase |
| NCT03065062 |
Bimagrumab |
Phase 2/3 |
Sarcopenia |
Improved muscle mass and function |
| NCT ID |
Intervention |
Phase |
Disease |
Status |
| NCT05645619 |
Follistatin gene therapy |
Phase 1 |
Sarcopenia |
Recruiting |
| NCT05782368 |
Myostatin antibody |
Phase 1 |
ALS |
Active |
- Serum Myostatin: Decreased levels with therapy
- Activin A: Modulated levels in blood and CSF
- Follistatin: Increased circulating levels
- Irisin: Elevated from increased muscle activity
- CSF neurofilament light chain (NfL): Marker of neuroaxonal injury
- p-tau181: AD progression marker
- Alpha-synuclein: PD progression marker
- Motor unit number estimation (MUNE): ALS progression
- Creatine kinase: Muscle health indicator
- Grip strength: Functional muscle assessment
- Appendicular lean mass: MRI-based measurement
- 6-minute walk test: Functional capacity
Disease-Modifying Potential:
- May slow cognitive decline in AD through muscle-brain cross-talk
- Motor function preservation in PD
- Sarcopenia management across all neurodegenerative diseases
- Potential to extend independent living
Quality of Life Improvements:
- Maintained mobility and independence
- Reduced fall risk
- Improved respiratory function
- Enhanced daily activity capacity
Blood-Brain Barrier:
- Peripheral myostatin inhibition may not directly affect CNS
- Gene therapy targeting muscle may not impact brain pathology
- BBB-penetrant small molecules under development
Dosing and Timing:
- Optimal timing relative to disease stage unclear
- Chronic administration may be required
- Combination with brain-penetrant therapies may be needed
Patient Selection:
- Biomarkers to predict response needed
- Patients with significant sarcopenia may benefit most
- Early intervention may be most effective
- Combination Therapy: May be combined with disease-modifying AD/PD therapies
- Adjunct to Exercise: Enhances benefits of physical therapy
- Preventive Use: Could be considered in at-risk populations with sarcopenia
- Monitoring: Regular muscle function and cognitive assessments
¶ Research Challenges and Future Directions
- CNS Effects: Unclear whether peripheral myostatin inhibition affects brain pathology
- Optimal Target: Whether to target myostatin, activins, or both
- Combination: Best approach with existing disease-modifying therapies
- Biomarkers: Need validated predictive biomarkers for patient selection
- BBB-Penetrant Inhibitors: Small molecules crossing the blood-brain barrier
- Muscle-Targeted Gene Therapy: AAV delivery to muscle only
- Dual-Targeting: Myostatin + activin A inhibition
- Biomarker Development: Predictive biomarkers for therapy response
- Population: Early-stage patients with measurable sarcopenia
- Endpoints: Cognitive and motor function, muscle mass, quality of life
- Duration: Long-term studies (12+ months) for disease-modifying effects
- Biomarker Integration: Correlate peripheral and CNS biomarkers